Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
By F. D. S. E. Melo, Xin Wang, M. Jansen, E. Fessler, A. Trinh, L. Rooij, J. Jong, O. J. Boer, Ronald van Leersum, M. Bijlsma and 8 more. Nature Medicine, 2013
772 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/24bfa78b9b2155ddf7d48687bf89f5603779a414
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. (2014, background): “We and others have proposed gene expression-based molecular subgroups [3-6] that share (groups of) molecular characteristics while maintaining significant intragroup heterogeneity.”
- CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models (2017, background): “For example, the CMS4 marker VIM is expressed in fibroblasts, but have higher expression among CMS4 cancer cells than CM2–3 and is therefore a useful template gene.”
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013, background): “Other gene expression-based analysis described three groups of CRC patients [23], which correlated with two of the known molecularly defined groups, namely the MSI (renamed CCS2) and the CIN (CCS1) groups, whereas the third group corresponded partly with the CIMP group (CCS3).”